The Patent on the Cure

The cure exists. That's the part worth sitting with.

Not in some theoretical sense — not "we're close" or "trials look promising." The mRNA vaccines for COVID-19 are here, manufactured, being injected into arms across the wealthy world at an accelerating pace. The science worked. Humanity cracked the code on a novel coronavirus in under a year, which is genuinely one of the most extraordinary achievements our species has pulled off. We should be taking a moment to appreciate the sheer improbability of that.

Instead, 175 former heads of state and Nobel laureates just had to write a letter to Joe Biden asking him to please let the rest of the world make the thing.

The letter, coordinated by the People's Vaccine Alliance, asks the Biden administration to support a proposal from South Africa and India at the World Trade Organization — a temporary waiver of the TRIPS agreement, which governs intellectual property rights in international trade. The waiver would allow countries to manufacture COVID-19 vaccines without licensing agreements from the original developers. Gordon Brown signed it. François Hollande signed it. Ellen Johnson Sirleaf. Joseph Stiglitz. Muhammad Yunus. Twenty-four Nobel laureates in chemistry alone.

They're not asking for anything radical. They're asking for the temporary suspension of a trade rule during a pandemic that has killed millions of people. The fact that this requires a letter from 175 of the most credentialed humans on the planet tells you something about the architecture of the system they're petitioning.

Here's the math that makes the letter necessary: more than 700 million vaccine doses have been administered worldwide. Eighty-seven percent have gone to wealthy countries. Low-income countries have received 0.2 percent. In high-income nations, roughly one in four people has received a dose. In low-income countries, it's one in 500. The entire continent of Africa has administered about 2 percent of the world's supply. Haiti hasn't received a single dose.

The vaccines work. The manufacturing knowledge exists. The bottleneck is a legal fiction — the intellectual property regime that grants exclusive production rights to a handful of pharmaceutical companies, several of which developed their vaccines with billions in public funding.

This is the pattern worth naming: we built a system that optimizes for return on investment, and then we deployed it against a crisis that requires speed and universal coverage. The system is performing exactly as designed. It's just that what it's designed for and what we need are two different things. The IP framework isn't malfunctioning. It's functioning — in a context where its function produces mass death in the places least able to absorb it.

Over 100 pharmaceutical lobbyists are currently working to oppose the waiver. Two-thirds of WTO member states support it. The math here isn't complicated. The politics are.

There's a version of this story that's about good guys and bad guys — greedy pharma versus noble global south. But the coherence lens suggests something less comfortable: the system that produced the vaccines in record time is the same system that now hoards them. The profit motive that incentivized the research is the same profit motive that restricts the distribution. You can't celebrate the engine and then act surprised by the exhaust.

The question isn't whether the waiver is the right policy. It's whether we've built a world where the cure for a global pandemic can be proprietary. We have. That's the fact on the table.

175 people who used to run countries are writing letters about it. The rest of us are watching the math.

Sources:

• Former heads of state and Nobel laureates call on President Biden to waive intellectual property rules for COVID vaccines — Oxfam International, 2021-04-14
• Low-income countries have received just 0.2 per cent of all COVID-19 shots given — UN News, 2021-04-09